Research Evidence Anecdotal Efficacy Side Effects Price Dosing & Protocol Regulatory Safety Notes

Pentosan Polysulfate

Pentosan Polysulfate is a semi-synthetic sulfated polysaccharide primarily utilized for interstitial cystitis relief and joint health support. While clinical protocols typically involve a daily subcutaneous dose of 100 mg, the broader evidence base for these applications remains thin, with many exploratory indications lacking published results. Users should note that the registered trial program shows a 25% withdrawal rate, and all human use is currently off-label or compounded. Injection-site reactions occasionally surface in community reports, while other common side effects like nausea, fluid retention, or histamine responses have not been consistently observed.

Half-life~20 h

Data last updated August 3, 2026

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Pentosan Polysulfate holds a moderate evidence tier, supported by thirteen published human studies primarily focused on treatment and mechanistic research. While the literature includes Phase 3 trials, the clinical record is fragmented; of the eight registered trials, only one has posted results, and the research spans ten distinct indications with a high concentration of single-trial, exploratory data. Prospective users should note a 25% withdrawal rate across the three distinct sponsors, signaling that while the peptide has been studied at scale, the breadth of validated clinical outcomes remains thin.

Depthhow much

8 registered trials

3 completed · 1 with posted results · 3 recruiting / active · combined n=8

Breadthhow many areas

10 indications mapped

7 thin / exploratory · 1 animal-only · 6 single-trial long-tail

Qualityhow rigorous

Highest tier: Phase 3

3 distinct sponsors · 25% withdrawal rate · AE table from NCT02930005 · 1 linked publication on registered trials

Breadth and depth37 rows captured

Human

direct clinical signal

21

Animal

translational support

12

In vitro

mechanistic support

4

HighMediumLow

Source data

Every row behind the score.

37 total

RCTNCT00003825Phase 3 · 1999 · n=174 · Radiation Therapy Oncology Group

Diarrhea

result Completed; results not posted

RCTNCT00086684Phase 4 · 2003 · n=369 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Interstitial Cystitis

tested Number of Responders Defined as Having at Least a 30% Reduction in the O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) From Baseline to Study Endpoint

result +3.0 participants (Number of Responders Defined as Having at Least a …)

Terminated: Interim Analysis showed that study continuation was futile. No safety concerns were raised during the trial.

RCTNCT00236990Phase 2 · n=283 · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Prostatitis

tested The change in total NIH-CPSI score from baseline to Week 12

result Completed; results not posted

RCTNCT02930005Phase 2 · 2015 · n=8 · The University of Texas Health Science Center, Houston

Psychotic Disorders

tested Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score

result −31.0 score (Change in Cognitive Function as Assessed by the NI…)

Small sample; effect at the edge of clinical significance.

RCTNCT03549650Phase 2 · 2019 · n=3 · Sir Mortimer B. Davis - Jewish General Hospital

Lower Urinary Tract Symptoms

tested Determine the efficacy (Urgency episodes assessed by bladder diary) a of co-administration of Pentosan Polysulphate in preventing BCG-related LUTS in adult subjects with a diagnosis of NMIBC.

result Terminated before completion

Terminated: Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to terminate the study.

RCTNCT04809376Phase 2 · 2021 · n=602 · Paradigm Biopharmaceuticals USA (INC)

Osteoarthritis, Knee

tested Change from baseline at Day 56 in knee pain as assessed by the average pain sub-scale score of the WOMAC® NRS 3.1 Index.

result In progress (active-not-recruiting)

RCTNCT05245591Phase 2 · 2022 · n=72 · National Taiwan University Hospital

Radiation Cystitis

tested Rate of complete remission in lower urinary tract symptoms and hematuria

result In progress (recruiting)

RCTNCT06917404Phase 3 · 2025 · n=466 · Paradigm Biopharmaceuticals Ltd.

Osteoarthritis, Knee

tested Change from baseline at Day 112 in knee pain as assessed by the weekly average of daily pain (ADP) score on the numerical rating scale (NRS) 11-point (0-10) scale.

result In progress (recruiting)

RCTPMID 2442417n=62

Treatment studies

tested pain, urgency, frequency, nocturia, average voided volumes, daily voiding episodes

result Significant subjective improvement in pain, urgency, frequency, nocturia vs placebo; objective voided volume improvement greater with drug vs placebo (p=0.009); no sig diff in daily voiding episodes.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

StudPMID 10073500

Treatment studies

tested symptoms, thrombolytic status, platelet activation threshold, plasma triglyceride levels

result In OA patients given CaPPS or NaPPS orally or parenterally in open and double-blind trials, symptoms and hematologic parameters (thrombolytic status, platelet activation, triglycerides) normalized.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CasePMID 23766840n=1

Treatment studies

tested symptom relief of dysuria, urgency, frequency, lower abdominal pain prior to cancer diagnosis

result Pentosan sulfate reduced severely debilitating IC symptoms and improved quality of life in 1 patient later found to have recurrent cervical adenocarcinoma.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenPMID 2438758n=10

Treatment studies

tested subjective and objective improvement in keratoconjunctivitis sicca

result No subjective or objective improvement recorded in 10 women treated with 150 mg x2 daily for 4 months.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenPMID 36879559n=38

Treatment studies

tested lipid levels (total cholesterol, LDL, triglycerides), knee pain NRS, KOOS, knee MRI semi-quantitative score

result Total cholesterol 6.23→5.95 mmol/L (P=0.01), LDL 4.03→3.82 mmol/L (P=0.009); knee pain NRS 6.39→4.18/3.63/4.38 at wks 6/16/26 (P<0.001); triglycerides NS.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CasePMID 37643033n=1

Diagnostic & mechanistic studies

tested visual acuity and retinal architecture after PPS discontinuation

result After PPS cessation: partial improvement in visual acuity and outer retinal architecture on OCT, but persistence of RPE atrophy and autofluorescence changes; choroidal neovascular membrane present in right eye.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 39174300n=13

Diagnostic & mechanistic studies

tested retinal thickness, choroidal volume, hyperreflective RPE excrescence volume post-cessation

result Mean retinal thickness lower at baseline vs controls (269.1 vs 290.2 µm, P=0.006); continued to decrease 11.3 µm over 18.6-month follow-up (P<0.001); RPE excrescence volume unchanged.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 39787060

Diagnostic & mechanistic studies

tested prevalence and incidence of pigmentary maculopathy/retinopathy; visual acuity changes

result PM/PR/PPS incidence 0.13–0.15 per 100 person-years in PPS-exposed cohorts; crude PM/PR/Any incidence similar across all cohorts (2.13–2.81 vs 2.38 per 100 person-years); PM/PR patients had ~2-fold higher rate of ≥3-line VA worsening.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CasePMID 41492572n=1

Treatment studies

tested bilateral PPS-associated retinopathy with macular and peripheral retinal degeneration

result Bilateral hand motion visual acuity after 26-yr PPS use (400mg/day, ~3769g cumulative); confluent nummular retinal atrophy, severe outer retinal disorganization, extensive RPE loss, absent Robson Holder ring.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CasePMID 41785987n=8

Diagnostic & mechanistic studies

tested GI pathology (adenomatous polyposis, dysplasia, IBD) and maculopathy stage progression

result 75% had severe adenomatous polyposis; 3 required colectomy; 37.5% of eyes showed maculopathy progression; cRORA present in 75% at follow-up; median latency to GI diagnosis 10 years post-PPS initiation.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 41962908n=187

Treatment studies

tested Risk factors for PPS maculopathy (retinal toxicity); prevalence among users

result Highest exposure quartile (≥2000 g): OR 39.8 (95% CI 10.6–205.1); female sex OR 8.1; prevalence estimated 3.8%–24.5% among PPS users.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 41989996n=6418

Treatment studies

tested visual acuity change from baseline over 36 months (logMAR/letters)

result PPS-exposed cohort lost ~1.63 letters at 36 months vs ~1.87 in controls; no evidence PPS exposure impacted visual acuity progression vs matched controls over 36 months.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenPMID 6191049n=24

Treatment studies

tested pain, urgency, and nocturia

result 20/24 patients had ≥80% decrease in pain, urgency, nocturia within 4–8 weeks; 2 had 50–80% decrease; 22 responders showed progressive improvement over time.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

AnimalPMID 11950161